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Diurnal Variation in Plasma Norepinephrine in Patients
with Heart Failure
Barry E. Bleske, Pharm. D., FCCP, Hui-San Chung, Matthew DiMagno, M.D., and John M. Nicklas, M.D.
Diurnal variation in plasma norepinephrine (PNE) levels is well documented
in healthy individuals but not in patients with heart failure.  Therefore, we
attempted to determine variations in PNE levels over 24 hours, measured
hourly, in six patients with an ejection fraction below 40% and a history of
heart failure of longer than 3 months.  Three controls without a history of
heart failure also were evaluated.  Both patients and controls had diurnal
variations in PNE, with highest levels occurring during the day and lowest at
night.  When data in patients were evaluated by 6-hour time intervals the
mean value for 6:00 A.M.–12:00 noon was approximately twice as high as
12:00 midnight–6:00 A.M. (689 ± 329 vs 338 ± 166 pg/ml, p<0.05,
respectively).  Patients also had significant peak to trough variation in PNE
levels compared with controls (959 ± 396 vs 386 ± 84 pg/ml, p<0.02,
respectively).  These results suggest that significant intrapatient variations in
PNE occur over 24 hours in patients with heart failure.  These variations may
have to be accounted for when evaluating and treating patients with heart
failure.
(Pharmacotherapy 1999;19(8):984–988)
Plasma norepinephrine is a prognostic marker
for mortality and disease severity in patients with
heart failure.1–3 However, in most trials,
conclusions were based on norepinephrine levels
obtained at only one time throughout 24 hours.
This may not be appropriate, since subjects
without heart failure have significant diurnal
variations in plasma norepinephrine concen-
trations over 24 hours.4, 5 Peak levels occur in
the morning hours and trough concentrations
during sleep at night.  Furthermore, in patients
with heart failure, diurnal variations in other
variables occur, including blood pressure, heart
rate, magnesium, and another neurohormone,
atrial natriuretic peptide.6–10 However, data are
very limited with regard to diurnal variations in
norepinephrine concentrations, which may have
important implications for studying and treating
these patients.
Methods
Six patients with heart failure and three
controls (patient spouses) were enrolled in this
pilot study.  Inclusion criteria for patients were a
confirmed diagnosis of chronic heart failure of
more than 3 months’ duration and secondary to
ischemic or idiopathic causes, and systolic
dysfunction (left ventricular ejection fraction
≤ 40%) measured within the past year.  All
participants had an entrained sleep-wake cycle,
with sleeping hours occurring between 12:00
midnight and 5:00 A.M. minimum.  Controls
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were excluded if they had a history of heart
failure or were receiving drugs that could alter
their sleep-wake cycle.
Participants were admitted to the clinical
research center.  A peripheral venous catheter
was placed in a forearm vein, and blood samples
were drawn every hour for 24 hours into chilled
Vacutainer tubes containing heparin to measure
norepinephrine concentrations.  All samples were
obtained in a darkened room with subjects lying
supine for a minimum of 20 minutes.  Samples
were immediately placed on ice, processed, and
frozen at -70°C.  Subjects were required to be in
bed by 11:00 P.M. and out of bed at 7:00 A.M.
Meals were provided at 8:00 A.M., noon, and 5:00 P.M.
Plasma norepinephrine concentrations were
determined by high-performance liquid
chromatography.11 Interday and intraday
coefficient of variation was less than 10%.
Cosinor analysis was performed to determine if
data showed a significant rhythmic variation with
respect to time.  Analysis of variance and Tukey’s
studentized range test were used to evaluate the
data when placed in specific time periods.
Regression analysis and unpaired t tests were
employed where appropriate.  A p value of 0.05
or less was considered the critical level.  Data are
reported as mean ± SD.
Results
Participant demographics are shown in Table 1.
Five of six patients were receiving diuretics, and
five were receiving angiotensin-converting
enzyme inhibitors and/or digoxin.  All patients
had maintained a stable drug regimen for at least
2 weeks before the study.  No subjects were
receiving drugs that could alter sleep patterns.
The overall mean norepinephrine concentrations
were 532 ± 316 pg/ml for patients and 330 ± 173
pg/ml for controls (p<0.001).  Mean hourly
norepinephrine levels for patients and controls
are illustrated in Figure 1.  Levels in both groups
showed similar overall changes, with lowest
concentrations occurring during sleep and
highest while awake, with a surge in morning
hours.  A significant cosinor rhythm was
observed in eight of the nine subjects, suggesting
diurnal variation in concentrations.  When the
data were evaluated by time intervals (Table 2),
the highest mean levels of norepinephrine
occurred between 6:00 A.M. and noon in patients
and between noon and 6:00 P.M. in controls.  In
fact, in patients with heart failure, the mean value
for 6:00 A.M.–noon was twice as high as that for
midnight–6:00 A.M., which was statistically
significant (p<0.05).
When mean norepinephrine levels were
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Table 1.  Patient Demographics
Age Etiology NYHA Ejection
(yrs) Sex of HF Class Fraction (%) Concurrent Drugs
Patients with heart failure (n=6)
58 F ID I 16 Furosemide, warfarin, KCl, digoxin
61 M IS II 40 Furosemide, nitroglycerin, KCl, ranitidine, aspirin
78 F ID II 26 Digoxin, bumetanide, warfarin, KCl, quinine, aspirin,
spironolactone
65 F IS NA 23 Enalapril, aspirin, spironolactone, quinidine, KCl, lovastatin
59 M ID IV 14 Digoxin, enalapril, KCl, bumetanide, warfarin, insulin




61 F Estrogen, probucol, piroxicam
66 M None
HF = heart failure; ID = idiopathic; IS = ischemic; NYHA = New York Heart Association; NA = not available.
Figure 1. Mean plasma norepinephrine concentrations over
24 hours.  Squares represent patients and triangles represent
controls.  NE = norepinephrine.
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correlated with levels at each time point,
regression values were for the most part high
(Figure 2).  The highest values occurred in the
afternoon between noon and 6:00 P.M.
(0.78–0.98).  When peak levels were correlated
with each time point, the correlations were
overall lower except in the morning to early
afternoon (9:00 A.M.–1:00 P.M.; Figure 3).
In addition to diurnal variations, large
intrapatient variability in concentrations was
seen especially in patients with heart failure.  The
mean difference in peak to trough concentrations
in this group was significantly higher than in
controls (959 ± 396 vs 386 ± 84 pg/ml, p<0.02,
respectively).  Mean values for the hour-to-hour
variation were 153 ± 105 pg/ml in patients and
84 ± 50 pg/ml in controls (p<0.01).  For patients,
the lowest hour-to-hour variation occurred
during sleep and the highest between 8:00 A.M.
and noon (Figure 4).
Discussion
The results of this study reveal that patients
with mild heart failure have diurnal variations in
plasma norepinephrine, with the highest
concentrations occurring in the morning hours
and the lowest at night.  This is similar to control
subjects.  However, patients had greater variation
in concentrations within 24 hours than controls,
as demonstrated by differences in peak to trough
concentrations and hour-to-hour variations.
Levels measured at each time point appear to
reflect overall mean norepinephrine levels but do
not routinely reflect peak levels.
Such variations in patients and controls are
similar to what was reported in subjects without
heart failure.4, 5 One group investigated
norepinephrine levels in patients with heart
failure over 24 hours.12 However, interpretation
of this study is difficult since mean values at each
time point were not reported and cosinor analysis
appeared not to be employed.  This study did
suggest that patients with heart failure had less
daytime variability than controls, although, it
appears that patients in that study had a higher
mean amplitude (difference between peak and
trough concentrations)13 than controls.  The
mean amplitude values we calculated were 217 ±
479 pg/ml for patients and 44 ± 24 pg/ml for
controls, approximately a 4-fold difference,
which is similar to our findings.
Levels we obtained during waking hours were
highly correlated with the 24-hour mean level.
This suggests that levels may be measured at any
time during waking hours without regard to
diurnal variation.  Another group found a similar
correlation between the level at 8:00 A.M. and the
overall mean level (r=0.78) but did not test other
time points.12 However, we found that levels at
each time period were not highly correlated with
peak levels except for a few time points in the
morning and early afternoon (9:00 A.M.–1:00
P.M.).  Thus a single level measured at any time
point may not be adequate to reflect peak levels.
Unfortunately, it is difficult to interpret these
findings for the clinical setting since it is not
known whether mortality or morbidity is better
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Table 2.  Mean Norepinephrine Levels (pg/ml) over 6-
Hour Intervals
Time Patients Controls
6:00 A.M.–noon 689 ± 329 349 ± 147
Noon–6:00 P.M. 613 ± 249 382 ± 166
6:00 P.M.–midnight 492 ± 206 341 ± 222
Midnight–6:00 A.M. 338 ± 166a 248 ± 127
ap<0.05 compared with 6:00 A.M.–noon.
Figure 2. Correlation coefficients between overall mean
norepinephrine concentrations and concentrations at each
measured time point in patients.  r = correlation coefficient.
Figure 3. Correlation coefficients between peak
norepinephrine concentrations and concentrations at each
measured time point in patients.  r = correlation coefficient.
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correlated with 24-hour mean levels or peak
levels in patients with heart failure.  At this time,
since previous studies evaluating the relationship
between norepinephrine levels and outcomes
examined only one level, it may be reasonable to
conclude that they reflected a patient’s mean level
when evaluated over 24 time points.
However, the results of this study raise an
important question as to whether mean or peak
norepinephrine concentrations are the most
important with regard to outcomes in patients
with heart failure.  Since a single level is likely
not to reflect peak concentrations, only one
measurement may not be adequate for quanti-
fying peak concentrations.  It should be noted
that overall, most cardiovascular events occur in
the morning hours and may be related in part to
a surge in catecholamine levels during that
time.13, 14 Thus quantifying peak norepinephrine
concentrations may be more important than
quantifying mean concentrations.
Another concern raised by this study, despite
the high correlation between time points and
mean levels, is the high hour-to-hour variability
in levels.  Since the correlation between mean
levels and individual time points is not equal to
1, a norepinephrine level measured at one time
point may suggest one prognosis and at the next
time point another prognosis.  This concern is
especially apparent in the morning hours when
the highest hour-to-hour variation occurred.
Theoretically, based on current practice of
measuring only one level, a patient’s prognosis
may change depending on what time of day the
level is drawn.  Future studies in which
norepinephrine concentrations are determined
may have to take into account this variation by
measuring several levels over 24 hours.
In addition to the diurnal variations in
norepinephrine levels observed in this study,
blood pressure, heart rate, and magnesium and
atrial natriuretic peptide concentrations are
associated with diurnal variations in patients
with heart failure.6–10 However, in some cases,
the magnitude of these variations may be less
than in controls.  Limited data suggest that for
blood pressure, heart rate, and atrial natriuretic
peptide, as the severity of heart failure worsens,
as determine by functional class or ejection
fraction, the variability in these values
decreases.6, 10 This may explain some of the
differences between our study and an earlier
one,12 since that group evaluated only patients
with classes III and IV heart failure, whereas five
of our six patients had class I or II disease.
However, this finding does not explain why one
patient did not show a significant cosinor rhythm
for norepinephrine concentrations.  Perhaps
other unknown factors contribute to norepi-
nephrine variability in patients with heart failure.
This study has several limitations including the
small number of subjects.  However, our findings
are consistent with other reports with regard to
diurnal variations in plasma norepinephrine, so
the number of patients evaluated, methods, and
results are probably appropriate.4, 5 Another
limitation is that the patients had mild disease.
Potentially, patients with more severe heart
failure may have less variability than we
observed.  In addition, the study enrolled a
heterogeneous population consisting of patients
with both ischemic and idiopathic cardio-
myopathies, which limits interpretation of data.
Not all patients were taking the same drugs,
which also theoretically affect our results and
contribute to the variability; however, most
patients were receiving standard therapy.
Furthermore, no available data suggest that
drugs, including b-blockers, alter overall
circadian patterns.  Drugs may limit peak or
trough variation in a circadian pattern, but the
overall pattern remains intact.  Digoxin
theoretically may increase variability in
norepinephrine levels over that in patients not
receiving the agent, if it restores sympathetic and
parasympathetic balance.
The diurnal variations and hour-to-hour
variations in norepinephrine levels in patients
with mild heart failure may have to be accounted
for when evaluating norepinephrine for
prognostic purposes, in designing research trials,
and potentially for prescribing optimal drug
therapy.
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Figure 4. Mean difference in norepinephrine
concentrations measured from one time point to the next in
patients.  NE = norepinephrine.
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